Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidanc...((lamivudine) (trademark of GSK) (EPZI...)

(EPZICOM)

FIRAZYR(R) (icatibant) (trademark of Jerini)

FOSRENOL(R) (lanthanum carbonate)

INTUNIV(TM) (guanfacine - extended release)

JUVISTA(R) (human TGFIsquared3) (trademark of Renovo)

LIALDA(R) (mesalamine)

METAZYM(TM) (arylsulfatase-A)

MEZAVANT(R) (mesalazine)

PENTASA(R) (mesalamine) (trademark of Ferring)

PLICERA(TM) (isofagomine tartrate) (trademark of Amicus)

RAZADYNE(R) (galantamine) (trademark of Johnson & Johnson

("J&J"))

RAZADYNE(R) ER (galantamine) (trademark of J&J)

REMINYL(R) (galantamine hydrobromide) (UK and Republic of

Ireland)

REMINYL (galantamine) (trademark of J&J, excluding UK

and Republic of Ireland)

REMINYL XL(TM) (galantamine hydrobromide) (UK and Republic of

Ireland)

REMINYL XL (galantamine) (trademark of J&J, excluding UK

and Republic of Ireland)

REPLAGAL(R) (agalsidase alfa)

VYVANSE(TM) (lisdexamfetamine dimesylate)

XAGRID(TM) (anagrelide hydrochloride)

ZEFFIX (lamivudine) (trademark of GSK)

3TC (lamivudine) (trademark of GSK)

OVERVIEW OF US GAAP FINANCIAL RESULTS

1. Introduction

Summary of Q2 2008 Revenues from operations for the three months to June 30, 2008 increased by 35% to $775.6 million (2007: $574.9 million).

The operating loss for the three months to June 30, 2008 was $67.3 million (2007 loss: $1,775.1 million). The loss in the second quarter of 2008 was due to the $1
'/>"/>